Effect of a mind-body intervention Liuzijue for patients with chronic heart failure: a randomized controlled trial.

注册号:

Registration number:

ITMCTR1900002431

最近更新日期:

Date of Last Refreshed on:

2019-06-29

注册时间:

Date of Registration:

2019-06-29

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

身心运动六字诀改善慢性稳定性心力衰竭预后的随机对照试验

Public title:

Effect of a mind-body intervention Liuzijue for patients with chronic heart failure: a randomized controlled trial.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

身心运动六字诀改善慢性稳定性心力衰竭预后的随机对照试验

Scientific title:

Effect of a mind-body intervention Liuzijue for patients with chronic heart failure: a randomized controlled trial.

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900024178 ; ChiMCTR1900002431

申请注册联系人:

廖媛

研究负责人:

李恒

Applicant:

Yuan Liao

Study leader:

Heng Li

申请注册联系人电话:

Applicant telephone:

+86 15013035060

研究负责人电话:

Study leader's telephone:

+86 13729965885

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2356478870@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lh12818@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市番禺区大学城外环东路232号

研究负责人通讯地址:

广东省东莞市东城东路1号

Applicant address:

232 Outer Ring Road East, University Town, Panyu District, Guangzhou, Guangdong

Study leader's address:

1 Dongcheng Road East, Dongguan, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学

Applicant's institution:

Guangzhou University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019DHLL032

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

东莞东华医院伦理委员会

Name of the ethic committee:

Dongguan Donghua Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2019/5/31 0:00:00

伦理委员会联系人:

叶柳青

Contact Name of the ethic committee:

Liu Qingye

伦理委员会联系地址:

广东省东莞市东城东路1号

Contact Address of the ethic committee:

1 Dongcheng Road East, Dongguan, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

东莞东华医院

Primary sponsor:

Dongguan Donghua Hospital

研究实施负责(组长)单位地址:

广东省东莞市东城东路1号

Primary sponsor's address:

1 Dongcheng Road East, Dongguan, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

东莞市

Country:

China

Province:

Guangdong

City:

Dongguan

单位(医院):

东莞东华医院

具体地址:

东城东路1号

Institution
hospital:

Dongguan Donghua Hospital

Address:

1 Dongcheng Road East

经费或物资来源:

广州中医药大学青年科研培育项目

Source(s) of funding:

Optimization of acupuncture clinical trial evidence to recommendation scheme based on GRADE-EtD framework and piecewise polynomial mixed effect model

研究疾病:

慢性心力衰竭

研究疾病代码:

Target disease:

Chronic heart failure

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

身心干预组(六字诀组)与常规治疗组(步行组)进行对照研究,探讨身心运动六字诀改善慢性稳定性心力衰竭疗效及安全性。

Objectives of Study:

The mind-body intervention group (liuzijue group) and the conventional treatment group (walking group) were used to conduct a controlled study to explore the efficacy and safety of mind-body intervention in improving the stability of chronic stable heart failure.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合心衰诊断标准者;(2)年龄在50—75岁之间;(3)NYHA分级Ⅰ-Ⅲ级;(4)慢性心力衰竭症状、体征稳定 1 个月以上;(5)意识清楚,听力、智力无明显障碍,能配合康复训练;(6)签署进入该研究知情同意书者。

Inclusion criteria

(1) Those who meet the diagnostic criteria for heart failure; (2) aged 50 to 75 years; (3) NYHA grade I-III; (4) the symptoms and signs of chronic heart failure are stable for more than 1 month; (5) consciousness, no obvious obstacles in hearing and intelligence, can cooperate with rehabilitation training; (6) sign the informed consent form.

排除标准:

(1)合并严重肾、肝功能不全、慢阻肺或肺心病患者;(2)合并严重造血系统、肿瘤等严重原发性疾病;(3)心脏瓣膜病变、心肌病或先天性心脏病;(4)高血压控制不佳者(静息时,收缩压>200mmHg或舒张压>110mmHg);(5)其他代谢性问题,如高钾血症、低钾血症、急性甲状腺炎等;(6)近3个月习练过功法(包括六字诀、八段锦、太极拳等)的患者。

Exclusion criteria:

(1) Patients with severe renal or hepatic insufficiency, chronic obstructive pulmonary disease or pulmonary heart disease; (2) severe primary diseases such as severe hematopoietic system and tumor; (3) heart valve disease, cardiomyopathy or congenital heart disease; (4) poor control of hypertension (at rest, systolic blood pressure > 200mmHg or diastolic blood pressure > 110mmHg); (5) other metabolic problems, such as hyperkalemia, hypokalemia, acute thyroiditis, etc.; (6) Patients who have practiced the practice method in the past 3 months (including Liu Zi, Ba Duan Jin, Tai Chi, etc.).

研究实施时间:

Study execute time:

From 2019-09-20

To      2019-12-20

征募观察对象时间:

Recruiting time:

From 2019-09-20

To      2019-12-20

干预措施:

Interventions:

组别:

试验组

样本量:

38

Group:

experimental group

Sample size:

干预措施:

六字诀

干预措施代码:

Intervention:

Liuzijue

Intervention code:

组别:

对照组

样本量:

38

Group:

control group

Sample size:

干预措施:

常规治疗(步行)

干预措施代码:

Intervention:

Routine treatment (walking)

Intervention code:

样本总量 Total sample size : 76

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

东莞东华医院

单位级别:

三甲

Institution/hospital:

Dongguan Donghua Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

峰值耗氧量

指标类型:

主要指标

Outcome:

Peak oxygen consumption

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 50
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用SAS 9.2 软件完成程序编写和随机。

Randomization Procedure (please state who generates the random number sequence and by what method):

Programming and randomization with SAS 9.2 software.

盲法:

干预训练将集中在医院康复中心不同的治疗室进行,患者的主管医生、执行相关结果测试的工作人员、进行结果评估的研究人员以及负责分析的生物统计学家对分组不知情,以保证盲法的实施,但是由于本研究干预方法是非药物疗法,研究参与者和干预教练不可能在整个试验期间设盲。

Blinding:

Blind method for testers, evaluators, statisticians.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开数据日期:2020-05-20,详见广州中医药大学临床研究与数据中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Open data date: 2020-05-20, Guangzhou University of Chinese Medicine Clinical Research and Data Center

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据收集采用病例记录表,电子采集和管理系统由广州中医药大学临床研究与数据中心具体实施

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection uses a case record form, and the electronic collection and management system is implemented by the Clinical Research and Data Center of Guangzhou University of Traditional Chinese Medicine

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above